CenterWatch Launches Service Linking Global Investigators with Clinical Research Sponsors
CenterWatch announced a new service designed to assist biopharmaceutical companies and contract research organizations (CROs) in identifying and engaging investigative sites worldwide to conduct phase I through IV clinical trials.
Over the past several years, clinical research sponsors have become increasingly interested in recruiting skilled and active investigators from a larger and more diverse number of global regions. During this same period, the number of investigative sites exiting the clinical research enterprise has grown, as sites find it increasingly difficult to secure study grants. The new CenterWatch ‘Grant Notification Service’ is designed to match clinical research sponsors with currently active, experienced investigative sites and to provide an effective study grant generation tool for research professionals.
The service will be largely automated through the CenterWatch web site at www.centerwatch.com/trialwatch_signup and free of charge to use. By the end of September 2010, CenterWatch anticipates having 25,000 active global investigative sites registered on the service. In addition, CenterWatch anticipates handling three to five unique requests weekly from sponsor and CRO companies. Each specific request will generate a list of selected investigative sites to be contacted by the sponsor or CRO originating the request.
“We’re very pleased to be offering a new web-based service to the global investigative site community,” said Joan Chambers, CenterWatch Chief Operating Officer. “Our company has a long history of offering sites the opportunity to identify and secure study grants through our publications. We’re also excited to be providing sponsors and CROs with a quick and efficient way to identify and to ultimately contact viable investigative sites worldwide.”
Phase III SELECT-GCA Trial Results Lead to FDA Approval of Rinvoq for Giant Cell Arteritis
April 30th 2025Rinvoq (upadacitinib) becomes the first oral JAK inhibitor approved by the FDA for the treatment of giant cell arteritis in adults, following robust data from the Phase III SELECT-GCA trial demonstrating its efficacy in achieving sustained remission and reducing glucocorticoid exposure.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
